Document is current
Any future updates will be listed below
-
Authors
Sepulveda-Falla, Diego https://orcid.org/0000-0003-0176-2042
Sanchez, Justin S.
Almeida, Maria Camila
Boassa, Daniela
Acosta-Uribe, Juliana
Vila-Castelar, Clara
Ramirez-Gomez, Liliana
Baena, Ana
Aguillon, David
Villalba-Moreno, Nelson David
Littau, Jessica Lisa
Villegas, Andres
Beach, Thomas G.
White, Charles L. III
Ellisman, Mark
Krasemann, Susanne
Glatzel, Markus
Johnson, Keith A.
Sperling, Reisa A.
Reiman, Eric M.
Arboleda-Velasquez, Joseph F.
Kosik, Kenneth S.
Lopera, Francisco
Quiroz, Yakeel T.
-
Funding
Funding for this research was provided by:
National Institute of Aging (R01 AG054671)
Massachusetts General Hospital Executive Committee on Research
Alzheimer’s Association Research Grant
Deutsche Forschungsgemeinschaft (CellNetFAD # 458854216)
National Institute of Neurological Disorders and Stroke (RF1 NS110048)
National Institute of Neurological Disorders and Stroke (RF1 NS110048)
National Institute of Neurological Disorders and Stroke (UH3 NS100121)
Alzheimer’s Association Research Fellowship
Universidad de Antioquia
Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/22819-8)
Werner Otto Stiftung
Bundesministerium für Bildung und Forschung (UndoAD)
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 29 March 2022
Revised: 21 June 2022
Accepted: 1 July 2022
First Online: 15 July 2022
Declarations
:
: RAS has received personal compensation from AC Immune, Eisai, Roche, and Takeda, and research grant support from Eli Lilly and Janssen. YTQ, JFAV, EMR, FL are listed as co-inventors of a patent application for therapeutics modulating interactions between APOE and HSPG filed by MGB. All other authors have no competing interests.
